BioMarin Pharmaceutical Inc (BMRN)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
- Symbol
- BMRN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $12.04B
- 52 week range
- 49.26 - 70.98
Valuation
- Share price
- $62.21 (close of 2026-09-23)
- P/E (TTM)
- 163.71x
- Price to book
- 1.90x
- Price to free cash flow
- 16.31x
- Enterprise value
- $15.37B
- Book value per share
- $32.66
Price performance
| Period | Change |
|---|
| 1 day | -2.89% |
| 5 days | -3.48% |
| 1 month | -6.73% |
| 3 months | +10.11% |
| 6 months | +13.56% |
| Year to date | +4.68% |
| 1 year | +16.48% |
| 3 years | -28.09% |
| 5 years | -21.55% |
| 10 years | -36.13% |
| All time | +378.53% |
Profitability and growth
- Return on equity
- 5.73%
- Return on invested capital
- 5.13%
- Return on assets
- 4.59%
- Return on capital employed
- 5.99%
- Gross margin
- 77.73%
- Net margin
- 10.83%
- EBITDA margin
- 15.18%
- Revenue growth
- 12.87%
- Net income growth
- -18.26%
- Free cash flow growth
- 48.73%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.13%
- Current ratio
- 2.39x
- Net debt to EBITDA
- 8.63x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $3.22B
- Cost of revenue
- $717.44M
- Gross profit
- $2.50B
- EBITDA
- $489.04M
- Net income
- $348.90M
- Earnings per share
- $1.82
- Research and development
- $921.93M
- Shares outstanding
- 191.79M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $3.22B | $2.50B | $348.90M | $1.82 |
| 2024-12-31 | $2.85B | $2.27B | $426.86M | $2.25 |
| 2023-12-31 | $2.42B | $1.89B | $167.65M | $0.89 |
| 2022-12-31 | $2.10B | $1.59B | $141.56M | $0.76 |
| 2021-12-31 | $1.85B | $1.38B | $-64.08M | $-0.35 |
| 2020-12-31 | $1.86B | $1.34B | $854.03M | $4.72 |
| 2019-12-31 | $1.70B | $1.34B | $-23.85M | $-0.13 |
| 2018-12-31 | $1.49B | $1.18B | $-77.21M | $-0.44 |
| 2017-12-31 | $1.31B | $1.07B | $-117.04M | $-0.67 |
| 2016-12-31 | $1.12B | $907.23M | $-630.21M | $-3.80 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 77.73% | 10.83% | 5.73% | 5.13% |
| 2024-12-31 | 79.67% | 14.96% | 7.54% | 6.94% |
| 2023-12-31 | 78.01% | 6.93% | 3.39% | 3.12% |
| 2022-12-31 | 76.00% | 6.75% | 3.08% | 3.08% |
| 2021-12-31 | 74.52% | -3.47% | -1.50% | -1.91% |
| 2020-12-31 | 71.82% | 45.90% | 20.83% | -0.62% |
| 2019-12-31 | 78.91% | -1.40% | -0.76% | -1.83% |
| 2018-12-31 | 78.86% | -5.18% | -2.60% | -2.50% |
| 2017-12-31 | 81.59% | -8.91% | -4.17% | -1.04% |
| 2016-12-31 | 81.23% | -56.43% | -22.78% | -30.49% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $1.31B |
| 2024-12-31 | $942.84M |
| 2023-12-31 | $755.13M |
| 2022-12-31 | $724.53M |
| 2021-12-31 | $587.28M |
| 2020-12-31 | $649.16M |
| 2019-12-31 | $437.45M |
| 2018-12-31 | $493.98M |
| 2017-12-31 | $1.40B |
| 2016-12-31 | $789.68M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $724.96M | $181.41M |
| 2024-12-31 | $487.42M | $201.57M |
| 2023-12-31 | $62.57M | $207.10M |
| 2022-12-31 | $54.94M | $196.31M |
| 2021-12-31 | $208.96M | $197.26M |
| 2020-12-31 | $-28.95M | $189.71M |
| 2019-12-31 | $-96.76M | $159.87M |
| 2018-12-31 | $-124.41M | $148.82M |
| 2017-12-31 | $-207.98M | $140.26M |
| 2016-12-31 | $-376.22M | $134.64M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-26
- Consensus EPS estimate
- $1.13
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.79 |
| 2026-05-04 | - | - |
| 2026-02-23 | - | - |
| 2025-10-27 | - | - |
| 2025-08-04 | - | - |
| 2025-05-01 | - | - |
| 2025-02-20 | - | - |
| 2025-02-19 | - | - |
Filings and sources
- Company website
- biomarin.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades